Noncoding RNA-Mediated High Expression of PFKFB3 Correlates with Poor Prognosis and Tumor Immune Infiltration of Lung Adenocarcinoma
Xue Gu,Xiaoli Li,Xue Zhang,Li Tong,Ran Feng,Lei Liu,Hui Sun,Qing Zhang,Tingting Bian,Jianguo Zhang,Lihua Gao,Chenxi Zhang,Jian Liu,Yifei Liu
DOI: https://doi.org/10.2147/ott.s416155
IF: 4
2023-09-22
OncoTargets and Therapy
Abstract:Xue Gu, 1, &ast Xiaoli Li, 1, &ast Xue Zhang, 2, &ast Li Tong, 3 Ran Feng, 1 Lei Liu, 1 Hui Sun, 1 Qing Zhang, 1 Tingting Bian, 1 Jianguo Zhang, 1 Lihua Gao, 2 Chenxi Zhang, 4 Jian Liu, 2 Yifei Liu 1 1 Department of Pathology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People's Republic of China; 2 Department of Oncology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, People's Republic of China; 3 Department of Pathology, Affiliated Hospital of Nantong University, Dalian Medical University, Nantong, 226001, People's Republic of China; 4 Medical School of Nantong University, Nantong, 226001, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yifei Liu; Jian Liu, Email ; Background: There is growing evidence showing that 6-phosphofructo-2-kinase (PFKFB3) plays crucial roles in different types of human cancers, including LUAD; however, the specific mechanism by which PFKFB3 plays a role in LUAD remains unclear. Methods: We investigated the expression of PFKFB3 and explored the underlying mechanism as well as the correlation with immune markers using several online datasets, such as Tumor Immune Estimate Resource (TIMER), UALCAN, and the Cancer Genome Atlas (TCGA) databases, miRWalk, Targetscan, MiRDB and starBase database. Western blot and immunohistochemistry analysis were performed to verify the corresponding outcomes. Results: It was shown that the mRNA expression of PFKFB3 was lower in LUAD than in the normal tissues, while its protein expression was not consistent with the mRNA level. The expression of PFKFB3 was correlated with clinicopathological parameters and several signaling pathways. The potential long chain (lnc)RNA/microRNA/PFKFB3 axis and the possible mechanism by which tumor progression in LUAD is promoted was predicted. We obtained the LINC01798/LINC02086/AP000845.1/HAGLR-miR-17-5p-PFKFB3 axis after comprehensive analyses of expression, correlation, and survival. Moreover, the expression of PFKFB3 was positively correlated with immune cells and immune checkpoint expression, including PD-1, PD-L1 and CTLA-4. Conclusion: The present study demonstrated that noncoding RNAs mediated the upregulation of PFKFB3 and was associated with a poor prognosis and immune tumor infiltration in LUAD. Keywords: PFKFB3, miR-17-5p, lncRNA, tumor immune infiltration, PD-1/PD-L1 In accordance with 2020 global cancer statistics, the incidence of lung cancer accounted for 11.4% out of 19.3 million new cases, and its mortality rate was higher than that of all human cancers in both men and women. 1 LUAD is the most common histological subtype and is considered to be closely related to smoking habits. Currently, comprehensive treatment is the main therapy for lung cancer. Targeted and immunized drugs are available; however, the therapy for lung cancer depends on its subtype and stage, as well as tumor size and the general condition of the patients. 2 Even though much progress has been made in the treatment of lung cancer, the prognosis for patients is still disappointing; therefore, searching for a new prognostic molecular marker to help doctors diagnose and treat lung cancer is essential. 6-phosphofructo-2-kinase (PFKFB3), as well as fructose-2,6-bisphosphatase 3 (F26BP3) with a molecular weight of ~58 kDa belongs to the PFKFB family, which is a key enzyme in glycolysis progression. 3 PFKFB3 has been reported to be upregulated in a majority of human cancers, such as breast cancer (BC), 4 gastric cancer (GC), 5 colorectal cancer (CRC), 6 and nasopharyngeal carcinoma (NPC). 7 Recently, PFKFB3 has been identified as one of the new kinases involved in cell metabolism and plays an important role in regulating cell growth and the proliferation in GC. 5 The overexpression or overactivation of PFKFB3 is closely related to many tumor diseases and has become a new target for antitumor drug research and development; however, the specific mechanism is less clear. Therefore, exploring its pathogenic mechanism in LUAD is of great significance for clinical treatment. In the present study, we analyzed the expression of PFKFB3 along with its clinicopathological relationship and function in LUAD. We also investigated the upstream molecular of PFKFB3 and determined its correlation with immune cells or immune checkpoints. Taken together, the noncoding (nc)RNA-mediated axis related to PFKFB3 may pro -Abstract Truncated-
oncology,biotechnology & applied microbiology